Exact Mass: 692.380528

Exact Mass Matches: 692.380528

Found 154 metabolites which its exact mass value is equals to given mass value 692.380528, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Scillaren A

Bufa-4,20,22-trienolide,3-[(6-deoxy-4-O-b-D-glucopyranosyl-a-L-mannopyranosyl)oxy]-14-hydroxy-,(3b)-

C36H52O13 (692.3407741999999)


D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002018 - Bufanolides

   

Bismahanine

15-[9-hydroxy-3,5-dimethyl-3-(4-methylpent-3-en-1-yl)-3H,11H-pyrano[3,2-a]carbazol-8-yl]-5,8-dimethyl-5-(4-methylpent-3-en-1-yl)-6-oxa-17-azatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1,3,7,9,11(16),12,14-heptaen-14-ol

C46H48N2O4 (692.3613888)


Bismahanine is found in herbs and spices. Bismahanine is an alkaloid from the stem bark of Murraya koenigii (curryleaf tree). Alkaloid from the stem bark of Murraya koenigii (curryleaf tree). Bismahanine is found in herbs and spices.

   

Opiorphin

(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-amino-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-5-carbamimidamido-1-hydroxypentylidene]amino}-1-hydroxy-3-phenylpropylidene]amino}-1,3-dihydroxypropylidene]amino}-5-carbamimidamidopentanoic acid

C29H48N12O8 (692.3717888)


Opiorphin is an endogenous 5-residue opioid peptide (Gln-Arg-Phe-Ser-Arg) first isolated from human saliva. Initial research with mice shows the compound has a painkilling effect greater than that of morphine. It works by stopping the normal breakdown of enkephalins, natural pain-killing opioids in the spinal cord. Opiorphin originates from the N-terminal region of the protein PROL1 (proline rich, lacrimal 1) and inhibits three proteases: neutral ecto-endopeptidase (MME), ecto-aminopeptidase N (ANPEP) and a dipeptidyl peptidase DPP3. This protease inhibitory action extends the duration of enkephalins, which are natural pain killers that are released in response to specific potentially painful stimuli. Opiorphin, an opioid peptide, is a potent enkephalin-inactivating zinc ectopeptidases in human inhibitor. Opiorphin inhibits two enkephalin-catabolizing ectoenzymes, human neutral ecto-endopeptidase, hNEP (EC 3.4.24.11) with an IC50 value of 11 μM, and human ecto-aminopeptidase, hAP-N (EC 3.4.11.2). Opiorphin displays potent analgesic activity by activating endogenous opioid-dependent transmission[1][2].

   

beta-Casomorphin-7

2-[(2-{[(1-{2-[({1-[2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl}(hydroxy)methylidene)amino]-3-phenylpropanoyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-1-hydroxyethylidene)amino]-3-methylpentanoate

C36H48N6O8 (692.3533448000001)


   

PA(12:0/PGF1alpha)

[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]heptanoyl}oxy)-3-(dodecanoyloxy)propoxy]phosphonic acid

C35H65O11P (692.426427)


PA(12:0/PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/PGF1alpha), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGF1alpha/12:0)

[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]heptanoyl}oxy)-2-(dodecanoyloxy)propoxy]phosphonic acid

C35H65O11P (692.426427)


PA(PGF1alpha/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF1alpha/12:0), in particular, consists of one chain of one Prostaglandin F1alpha at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/PGF1alpha)

[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]heptanoyl}oxy)-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H65O11P (692.426427)


PA(i-12:0/PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/PGF1alpha), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGF1alpha/i-12:0)

[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]heptanoyl}oxy)-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H65O11P (692.426427)


PA(PGF1alpha/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF1alpha/i-12:0), in particular, consists of one chain of one Prostaglandin F1alpha at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   

Cherimolacyclopeptide C

Cherimolacyclopeptide C

C35H48N8O7 (692.3645778)


   
   
   
   
   
   
   
   
   

5-[(3S,8R,10R,13R,14S,17R)-3-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one

5-[(3S,8R,10R,13R,14S,17R)-3-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one

C36H52O13 (692.3407741999999)


   

[(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] 14-hydroxytetradecanoate

[(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] 14-hydroxytetradecanoate

C34H60O14 (692.398286)


   

Bayogenin base + O-HexA

Bayogenin base + O-HexA

C38H60O11 (692.413541)


Annotation level-3

   

jaspamide P

jaspamide P

C37H48N4O9 (692.3421118)


A cyclodepsipeptide isolated from Jaspis splendens. A derivative of jaspamide, it has been shown to exhibit cytotoxic and microfilament disruption activity.

   

16beta-acetoxy-3-O-beta-D-xylopyranosyl-22,25-epoxyholosta-9(11)-ene-3beta,12alpha,17alpha-triol|nobiliside C

16beta-acetoxy-3-O-beta-D-xylopyranosyl-22,25-epoxyholosta-9(11)-ene-3beta,12alpha,17alpha-triol|nobiliside C

C37H56O12 (692.3771576)


   

Scillirubrosidin 3-O-??-L-rhamnopyranosyl-(1鈥樏傗垎4)-??-L-rhamnopyranoside

Scillirubrosidin 3-O-??-L-rhamnopyranosyl-(1鈥樏傗垎4)-??-L-rhamnopyranoside

C36H52O13 (692.3407741999999)


   
   
   

sucrose ester MW 692

sucrose ester MW 692

C33H56O15 (692.3619026)


   

Medicagenic acid 3-O-beta-D-glucoside dimethyl ester

Medicagenic acid 3-O-beta-D-glucoside dimethyl ester

C38H60O11 (692.413541)


   

3,23-(2-hydroxyethylidene)-3beta,19alpha,23-trihydroxyurs-12-en-28-oic acid 28-O-beta-D-glucopyranosyl ester|oblonganoside J

3,23-(2-hydroxyethylidene)-3beta,19alpha,23-trihydroxyurs-12-en-28-oic acid 28-O-beta-D-glucopyranosyl ester|oblonganoside J

C38H60O11 (692.413541)


   

(18R)-18-O-beta-D-glucopyranosyl-(1-2)-beta-D-glucopyranoside of allo-murolic acid

(18R)-18-O-beta-D-glucopyranosyl-(1-2)-beta-D-glucopyranoside of allo-murolic acid

C33H56O15 (692.3619026)


   

25-(acetyloxy)-2-(beta-D-glucopyranosyloxy)-3,16-dihydroxy-9-methyl-19-norlanosta-5,23-dien-22-one

25-(acetyloxy)-2-(beta-D-glucopyranosyloxy)-3,16-dihydroxy-9-methyl-19-norlanosta-5,23-dien-22-one

C38H60O11 (692.413541)


   
   
   

(18S)-18-O-beta-D-glucopyranosyl-(1-6)-beta-D-glucopyranoside of protoconstipatic acid

(18S)-18-O-beta-D-glucopyranosyl-(1-6)-beta-D-glucopyranoside of protoconstipatic acid

C33H56O15 (692.3619026)


   

(18R)-18-O-beta-D-glucopyranosyl-(1-3)-beta-D-glucopyranoside of murolic acid

(18R)-18-O-beta-D-glucopyranosyl-(1-3)-beta-D-glucopyranoside of murolic acid

C33H56O15 (692.3619026)


   
   
   

19-[(1S,4R)-4-hydroxy-1-methoxy-2-oxopentyl]-4,5-dihydrogeldanamycin

19-[(1S,4R)-4-hydroxy-1-methoxy-2-oxopentyl]-4,5-dihydrogeldanamycin

C35H52N2O12 (692.3520072)


   

2alpha,3beta,19alpha-trihydroxyurs-12-en-28-oic acid 28-O-6-O-acetyl-beta-D-glucopyranosyl ester|potentillanoside C

2alpha,3beta,19alpha-trihydroxyurs-12-en-28-oic acid 28-O-6-O-acetyl-beta-D-glucopyranosyl ester|potentillanoside C

C38H60O11 (692.413541)


   

16,17-didehydro-23R,24R-O-acetylhydroshengmanol-3-O-beta-D-galactopyranoside

16,17-didehydro-23R,24R-O-acetylhydroshengmanol-3-O-beta-D-galactopyranoside

C38H60O11 (692.413541)


   

2alpha-acetoxyl-3beta,6beta-dihydroxylup-20(29)-en-28-oic acid beta-glucopyranosyl ester

2alpha-acetoxyl-3beta,6beta-dihydroxylup-20(29)-en-28-oic acid beta-glucopyranosyl ester

C38H60O11 (692.413541)


   

25-O-acetylcimigenol-3-O-beta-D-galactopyranoside

25-O-acetylcimigenol-3-O-beta-D-galactopyranoside

C38H60O11 (692.413541)


   
   

3-O-beta-D-glucopyranosylplatycogenic acid A lactone methyl ester

3-O-beta-D-glucopyranosylplatycogenic acid A lactone methyl ester

C37H56O12 (692.3771576)


   

Dehydroadynerigenin glucosyldigitaloside

Dehydroadynerigenin glucosyldigitaloside

C36H52O13 (692.3407741999999)


   
   

marinisporolide B

marinisporolide B

C38H60O11 (692.413541)


   

2-O-acetylsuavissimoside F1

2-O-acetylsuavissimoside F1

C38H60O11 (692.413541)


   

Antibiotic PD 118576A1

Antibiotic PD 118576A1

C37H56O12 (692.3771576)


   

3alpha-Methacryloyloxy-2beta-hydroxy-ent-labd-7-en-15-oic acid-2-O-beta-fucopyranoside methyl ester triacetate

3alpha-Methacryloyloxy-2beta-hydroxy-ent-labd-7-en-15-oic acid-2-O-beta-fucopyranoside methyl ester triacetate

C37H56O12 (692.3771576)


   

24-O-acetyl-25-O-methyl-7,8-didehydrohydroshengmanol 3-O-beta-D-xylopyranoside

24-O-acetyl-25-O-methyl-7,8-didehydrohydroshengmanol 3-O-beta-D-xylopyranoside

C38H60O11 (692.413541)


   
   

Antibiotic PD 118576A2

Antibiotic PD 118576A2

C37H56O12 (692.3771576)


   

(3beta,5alpha,6beta,8beta,15alpha,16beta)-3-O-[2,4-Di-O-methyl-beta-D-xylopyranoside],15-sulfate,Cholestane-3,6,8,15,16-pentol

(3beta,5alpha,6beta,8beta,15alpha,16beta)-3-O-[2,4-Di-O-methyl-beta-D-xylopyranoside],15-sulfate,Cholestane-3,6,8,15,16-pentol

C34H60O12S (692.380528)


   

3,3,5,8-Tetramethyl-3,3-bis(4-methyl-3-pentenyl)-9,9-dihydroxy-3,3,11,11-tetrahydro-8,10-bi[pyrano[3,2-a]carbazole]

3,3,5,8-Tetramethyl-3,3-bis(4-methyl-3-pentenyl)-9,9-dihydroxy-3,3,11,11-tetrahydro-8,10-bi[pyrano[3,2-a]carbazole]

C46H48N2O4 (692.3613888)


   

3-dodecanoyl-3-(2-methylbutanoyl)-4-(3-methylbutanoyl)sucrose

3-dodecanoyl-3-(2-methylbutanoyl)-4-(3-methylbutanoyl)sucrose

C34H60O14 (692.398286)


   

3-dodecanoyl-3,4-di(3-methylbutanoyl)sucrose

3-dodecanoyl-3,4-di(3-methylbutanoyl)sucrose

C34H60O14 (692.398286)


   

5-[(3S,8R,10R,13R,14S,17R)-3-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one

NCGC00169308-03!5-[(3S,8R,10R,13R,14S,17R)-3-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one

C36H52O13 (692.3407741999999)


   

[(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] 14-hydroxytetradecanoate

NCGC00380378-01![(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] 14-hydroxytetradecanoate

C34H60O14 (692.398286)


   

Monensin sodium salt

Monensin sodium salt

C36H61NaO11 (692.4111356)


Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis. Monensin sodium salt is an ionophore that mediates Na+/H+ exchange. Monensin sodium salt causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion[1][2][3][4].

   
   

Monensin A, Na salt

Monensin A, Na salt

C36H61NaO11 (692.4111356)


Origin: Microbe

   

Monensin A Na salt

Monensin A Na salt

C36H61NaO11 (692.4111356)


Origin: Microbe

   

Bismahanine

13-[9-hydroxy-3,5-dimethyl-3-(4-methylpent-3-en-1-yl)-3H,11H-pyrano[3,2-a]carbazol-10-yl]-5,8-dimethyl-5-(4-methylpent-3-en-1-yl)-6-oxa-17-azatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1,3,7,9,11,13,15-heptaen-14-ol

C46H48N2O4 (692.3613888)


   

PKODA-PG

1-hexadecanoyl-2-(9,12-dioxo-10E-dodecenoyl)-sn-glycero-3-phospho-(1-sn-glycerol)

C34H61O12P (692.3900435999999)


   

Transvaalin

3-O-(4-O-beta-D-glucopyranosyl-alpha-L-rhamnopyranosyl)-3beta,14beta-dihydroxybufa-4,20,22-trienolide

C36H52O13 (692.3407741999999)


   

Echinasteroside C 15-O-sulfate

(25S)-3beta-(2-O-methyl-beta-D-xylopyranosyloxy)-6beta,8,16beta,26-tetrahydroxycholest-5-en-15alpha-yl sulfate

C33H56O13S (692.3441446)


   

Bastaxanthin B

(3R,1R,5R)--19-hydroxy-3,6,17-trioxo-7,8-didehydro-beta,kappa-caroten-3-yl sulphate

C40H52O8S (692.3382712000001)


   

N,N-(methylenedi-p-phenylene)bis[N-[3-(triethoxysilyl)propyl]urea]

N,N-(methylenedi-p-phenylene)bis[N-[3-(triethoxysilyl)propyl]urea]

C33H56N4O8Si2 (692.3636496)


   

Z-Ala-Arg-Arg-AMC hydrochloride salt

Z-Ala-Arg-Arg-AMC hydrochloride salt

C33H44N10O7 (692.3394274)


   

(16alpha,20R,22S,23S)-16,23:22,25-diepoxy-2,20,22,23-tetrahydroxycucurbita-1,5-diene-3,11-dione 2-O-beta-D-glucopyranoside

(16alpha,20R,22S,23S)-16,23:22,25-diepoxy-2,20,22,23-tetrahydroxycucurbita-1,5-diene-3,11-dione 2-O-beta-D-glucopyranoside

C36H52O13 (692.3407741999999)


A triterpenoid saponin of the class of cucurbitane glycosides isolated from the roots of Machilus yaoshansis. It has been shown to exhibit inhibitory activity against protein tyrosine phosphatase.

   

Monensin Sodium

Monensin sodium salt

C36H61NaO11 (692.4111356)


D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D004791 - Enzyme Inhibitors > D014475 - Uncoupling Agents D007476 - Ionophores > D061209 - Proton Ionophores D007476 - Ionophores > D061210 - Sodium Ionophores D049990 - Membrane Transport Modulators Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis. Monensin sodium salt is an ionophore that mediates Na+/H+ exchange. Monensin sodium salt causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion[1][2][3][4].

   

Acylsucrose S4:21 [3]*

Acylsucrose S4:21 [3]*

C33H56O15 (692.3619026)


   

Sucrose-2,4-diisovaleroyl-3-laurate

Sucrose-2,4-diisovaleroyl-3-laurate

C34H60O14 (692.398286)


   

3-Lauryl-3,4-di(isovaleryl)sucrose

3-Lauryl-3,4-di(isovaleryl)sucrose

C34H60O14 (692.398286)


   

3-Lauryl-3-(2-methylbutanoyl)-4-(isovaleryl)sucrose

3-Lauryl-3-(2-methylbutanoyl)-4-(isovaleryl)sucrose

C34H60O14 (692.398286)


   

Sucrose-2-(2-methyl)butyryl-4-(2-methyl)butyryl-3-(4-methyl)hexanoyl-6-isobutyrate

Sucrose-2-(2-methyl)butyryl-4-(2-methyl)butyryl-3-(4-methyl)hexanoyl-6-isobutyrate

C33H56O15 (692.3619026)


   
   
   

PA(i-12:0/PGF1alpha)

PA(i-12:0/PGF1alpha)

C35H65O11P (692.426427)


   

PA(PGF1alpha/i-12:0)

PA(PGF1alpha/i-12:0)

C35H65O11P (692.426427)


   

H-DL-Tyr-DL-Pro-DL-Phe-DL-Pro-Gly-DL-xiIle-OH

H-DL-Tyr-DL-Pro-DL-Phe-DL-Pro-Gly-DL-xiIle-OH

C36H48N6O8 (692.3533448000001)


   

[(3S,6R,8S,9R,10R,13R,14S,15R,16R,17R)-3-[(2S,3S,5R)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy-6,8,16-trihydroxy-17-[(2R,6S)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,6,7,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-15-yl] hydrogen sulfate

[(3S,6R,8S,9R,10R,13R,14S,15R,16R,17R)-3-[(2S,3S,5R)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy-6,8,16-trihydroxy-17-[(2R,6S)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,6,7,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-15-yl] hydrogen sulfate

C33H56O13S (692.3441446)


   

2-[[(2R)-2-[(E)-7-carboxy-5-hydroxyhept-6-enoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-[(E)-7-carboxy-5-hydroxyhept-6-enoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO11P+ (692.4138518)


   
   
   
   
   
   
   
   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C38H61O9P (692.4052986)


   
   

[1-acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C33H56O15 (692.3619026)


   

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C33H57O13P (692.3536601999999)


   

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C33H57O13P (692.3536601999999)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C33H57O13P (692.3536601999999)


   

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C33H57O13P (692.3536601999999)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C37H57O10P (692.3689152)


   

2-[[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H63NO8P+ (692.4291068)


   

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H63NO8P+ (692.4291068)


   

Opiorphin

Opiorphin

C29H48N12O8 (692.3717888)


Opiorphin, an opioid peptide, is a potent enkephalin-inactivating zinc ectopeptidases in human inhibitor. Opiorphin inhibits two enkephalin-catabolizing ectoenzymes, human neutral ecto-endopeptidase, hNEP (EC 3.4.24.11) with an IC50 value of 11 μM, and human ecto-aminopeptidase, hAP-N (EC 3.4.11.2). Opiorphin displays potent analgesic activity by activating endogenous opioid-dependent transmission[1][2].